Acrivon Therapeutics (ACRV) Set to Post Earnings on Thursday

Acrivon Therapeutics (NASDAQ:ACRV) will likely be posting its Q3 2026 resultson Thursday, November 12th. Analysts expect Acrivon Therapeutics to announce earnings of ($0.45) per share and revenue of $0.50 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 16, 2026 at 4:00 PM ET.

Acrivon Therapeutics (NASDAQ:ACRV) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.07. On average, analysts expect Acrivon Therapeutics to post ($1.76) EPS for the current fiscal year and ($1.40) EPS for the next fiscal year.

Acrivon Therapeutics Stock Performance

NASDAQ ACRV opened at $1.58 on Tuesday. Acrivon Therapeutics has a 52-week low of $1.27 and a 52-week high of $3.56. The company has a fifty day moving average of $1.88 and a 200-day moving average of $1.76. The company has a market capitalization of $67.70 million, a P/E ratio of -0.84 and a beta of 1.96.

Wall Street Analysts Forecast Growth

ACRV has been the subject of several research analyst reports. Wall Street Zen lowered Acrivon Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings upgraded Acrivon Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 9th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $13.50.

Insider Activity

In other news, CEO Peter Blume-Jensen sold 14,036 shares of the company’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $2.21, for a total transaction of $31,019.56. Following the completion of the transaction, the chief executive officer directly owned 2,230,052 shares of the company’s stock, valued at approximately $4,928,414.92. This represents a 0.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 17,345 shares of company stock valued at $37,578 in the last 90 days. 10.50% of the stock is currently owned by insiders.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines for patients with difficult-to-treat cancers. The company uses its proprietary OncoSignature platform to identify tumor characteristics that may predict a patient’s response to a particular therapy, with the goal of matching treatments to the patients most likely to benefit.

Acrivon’s lead investigational product is ACR-368, an oral small-molecule therapy designed to target cell-cycle checkpoint mechanisms that cancer cells rely on for survival.